Translational Stroke Research

, Volume 2, Issue 2, pp 202–208

Minocycline Development for Acute Ischemic Stroke

  • Susan C. Fagan
  • Lydia E. Cronic
  • David C. Hess
Original Article

DOI: 10.1007/s12975-011-0072-6

Cite this article as:
Fagan, S.C., Cronic, L.E. & Hess, D.C. Transl. Stroke Res. (2011) 2: 202. doi:10.1007/s12975-011-0072-6

Abstract

Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood–brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.

Keywords

Minocycline Drug development Acute stroke Vascular protection 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Susan C. Fagan
    • 1
    • 2
    • 3
  • Lydia E. Cronic
    • 1
  • David C. Hess
    • 1
    • 3
  1. 1.Program in Clinical and Experimental TherapeuticsUniversity of Georgia College of PharmacyAugustaUSA
  2. 2.Charlie Norwood VA Medical CenterAugustaUSA
  3. 3.Department of NeurologyGeorgia Health Sciences UniversityAugustaUSA

Personalised recommendations